Jacobs Levy Equity Management’s Entrada Therapeutics TRDA Stock Holding History

Jacobs Levy Equity Management’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.23M	Sell	303,459 -30,455	-9%	-$292K	0.01%	574
2026 Q1	$4.21M	Sell	333,914 -28,872	-8%	-$331K	0.02%	453
2025 Q4	$3.73M	Buy	362,786 +46,976	+15%	+$396K	0.01%	464
2025 Q3	$1.83M	Buy	315,810 +95,074	+43%	+$556K	0.01%	608
2025 Q2	$1.48M	Buy	220,736 +9,863	+5%	+$79.4K	0.01%	683
2025 Q1	$1.91M	Sell	210,873 -1,844	-0.9%	-$23K	0.01%	669
2024 Q4	$3.68M	Buy	212,717 +10,914	+5%	+$198K	0.01%	482
2024 Q3	$3.22M	Buy	201,803 +67,559	+50%	+$1.06M	0.01%	512
2024 Q2	$1.91M	Buy	+134,244	New	+$1.91M	0.01%	607

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Jacobs Levy Equity Management's TRDA Position: Q2 2026 in Review

Jacobs Levy Equity Management reduced its Entrada Therapeutics (TRDA) stake by 9.1% in Q2 2026, selling an estimated $292K and leaving 303,459 shares worth $2.23M. The position accounts for 0.01% of the portfolio, ranked #574.

Jacobs Levy Equity Management first reported a position in TRDA in Q2 2024 and has held it in 9 quarters since. The position peaked at $4.21M in Q1 2026. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

Jacobs Levy Equity Management held 303,459 shares of Entrada Therapeutics worth $2.23M as of Q2 2026.
Jacobs Levy Equity Management sold 30,455 Entrada Therapeutics shares in Q2 2026, an estimated $292K.
Entrada Therapeutics made up 0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #574 holding.
Jacobs Levy Equity Management first reported a position in Entrada Therapeutics in Q2 2024 and has held it in 9 quarters since.
Jacobs Levy Equity Management's Entrada Therapeutics position peaked at $4.21M in Q1 2026.
129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.